These clinical and molecular characteristics arise from the participation of SOX2 in the formation and maintenance of tumor-initiating cells that resemble tissue progenitor cells, as evidenced by BRCA (45,60,61), GBM (52,62–64), LUAD (65) and LUSC (66) studies. Here, SOX2 is linked to neoplasm.